

## Erratum

In the original article by Wu, et al., entitled “Whole-Transcriptome Analysis of CD133+CD144+ Cancer Stem Cells Derived from Human Laryngeal Squamous Cell Carcinoma Cells” [Cell Physiol Biochem 2018;47(4):1696-1710, DOI: 10.1159/000490992], there have been 3 typographical errors in the title and discussion section, where “CD44+” has been written as “CD144+”.

The correct title section of the paper and the corrections of the respective sentences in the discussion section are shown below.

The authors sincerely apologize for this mistake.

## Whole-Transcriptome Analysis of CD133+CD44+ Cancer Stem Cells Derived from Human Laryngeal Squamous Cell Carcinoma Cells

Yongyan Wu<sup>a,b,c,d</sup> Yuliang Zhang<sup>a,b,c,d</sup> Min Niu<sup>a,b,c,d</sup> Yong Shi<sup>a,b,c,d</sup> Hongliang Liu<sup>a,b,c,d</sup>  
Dongli Yang<sup>a,b,c,d</sup> Fei Li<sup>a,b,c,d</sup> Yan Lu<sup>e</sup> Yunfeng Bo<sup>f</sup> Ruiping Zhang<sup>d,g</sup> Zhenyu Li<sup>d,h</sup>  
Hongjie Luo<sup>a,b,c,d</sup> Jiajia Cui<sup>a,b,c,d</sup> Jiangwei Sang<sup>a,b,c,d</sup> Caixia Xiang<sup>a,b,c,d</sup> Wei Gao<sup>a,b,c,d</sup>  
Shuxin Wen<sup>a,b,c,d</sup>

<sup>a</sup>Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Taiyuan, <sup>b</sup>Department of Otolaryngology Head & Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, <sup>c</sup>Otolaryngology Head & Neck Surgery Research Institute, Shanxi Medical University, Taiyuan, <sup>d</sup>The Key Scientific and Technological Innovation Platform for Precision Diagnosis and Treatment of Head and Neck Cancer, Shanxi Province, Taiyuan, <sup>e</sup>Department of Otolaryngology Head & Neck Surgery, The First Hospital, Jinzhou Medical University, Jinzhou, <sup>f</sup>Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan, <sup>g</sup>Department of MRI & CT, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan, <sup>h</sup>Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, China

On page 1706: “Previously, we isolated CD133+CD44+ cancer stem cells from LSCC cell lines, and functional study demonstrated stronger malignant behaviors in CD133+CD44+ LSCC stem cells than CD133+ or CD44+ LSCC stem cells, CD133-CD44- LSCC cells, and parental cells [6].”